AstraZeneca Taps Pieris For Inhaled Asthma Anticalins
AstraZeneca is to pay $57.5m to get its hands on biotech Pieris Pharmaceuticals' Anticalin technology to bolster its early stage respiratory portfolio, with a lead product candidate already being prepared for Phase I.
You may also be interested in...
Pieris And Seattle Strike IO Deal
Pieris secures another deal for its novel Anticalin technology – this time with Seattle in immuno-oncology.
End Of The Line For AstraZeneca’s Tralokinumab In Asthma
Another Phase III failure looks likely to spell the end for AstraZeneca’s tralokinumab in severe uncontrolled asthma. The company’s eyes are now firmly fixed on benralizumab.
Biopharma Quarterly Deal-Making Statistics, Q2 2017
Biopharma companies raised $13.4 billion in Q2, mostly through IPOs. Thanks to several billion-dollar deals in Q2, 2017 is shaping up to be a year of CRO consolidations. Big pharma continued divesting assets to smaller biopharma companies.